For the 2nd quarter (interim) of the fiscal year ending March 2027, consolidated results were: net sales 563 million yen, operating income 197 million yen, ordinary income 206 million yen, and net income attributable to owners of parent for the interim 186 million yen. Year-over-year, net sales +16.0%, operating income +38.9%, ordinary income +38.1%, and net income +31.7% improved. Full-year forecasts are net sales 1,087 million yen, operating income 322 million yen, ordinary income 322 million yen, net income attributable to owners of parent 347 million yen, and earnings per share 37.26 yen. Dividends are 0 yen at the end of the 2nd quarter, 0 yen at the end of the 3rd quarter, and a full-year forecast of 0 yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4570","jir_company_name":"Immuno-Biological Laboratories Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4570-20261111-01.pdf","jir_short_summary":"For the 2nd quarter (interim) of the fiscal year ending March 2027, consolidated results were: net sales 563 million yen, operating income 197 million yen, ordinary income 206 million yen, and net income attributable to owners of parent for the interim 186 million yen. Year-over-year, net sales +16.0%, operating income +38.9%, ordinary income +38.1%, and net income +31.7% improved. Full-year forecasts are net sales 1,087 million yen, operating income 322 million yen, ordinary income 322 million yen, net income attributable to owners of parent 347 million yen, and earnings per share 37.26 yen. Dividends are 0 yen at the end of the 2nd quarter, 0 yen at the end of the 3rd quarter, and a full-year forecast of 0 yen.","jir_summary":"### Overview of Results\nImmuno-Biological Laboratories Co., Ltd. recorded a significant increase in net sales in the 2nd quarter (interim) of the fiscal year ending March 2027, primarily driven by antibody-related businesses. Expansion of overseas sales, yen depreciation, and increased revenues from contract services and in-house in vitro diagnostic products contributed to the growth, resulting in total net sales of 563,168 thousand yen and operating income of 197,477 thousand yen, a substantial improvement year-over-year. Although sales in the cosmetics-related business declined, consolidated ordinary income was 206,867 thousand yen and net income attributable to owners of parent for the interim was 186,570 thousand yen, demonstrating steady growth. The financial position remains solid with an equity ratio of 86.4% and cash and cash equivalents of 822,660 thousand yen.\n\n### Outlook and Considerations\nFull-year forecasts are net sales 1,087,000 thousand yen, operating income 322,000 thousand yen, ordinary income 322,000 thousand yen, and net income attributable to owners of parent 347,000 thousand yen (earnings per share 37.26 yen). The interim results are progressing within the assumptions. Exchange rate movements and trends in contract services and overseas markets may impact performance, while growth in antibody-related businesses is expected to continue contributing to profits.","jir_financial_highlights":"Net Sales: 563,168 thousand yen (Year-over-Year +16.0%)\nOperating Income: 197,477 thousand yen (Year-over-Year +38.9%)\nOrdinary Income: 206,867 thousand yen (Year-over-Year +38.1%)\nNet Income Attributable to Owners of Parent (Interim): 186,570 thousand yen (Year-over-Year +31.7%)\nTotal Assets: 2,285,104 thousand yen (6.0% increase from the end of the previous consolidated fiscal year)\nEquity Ratio: 86.4%","jir_category":"","jir_hashtags":"#ImmunoBiologicalLaboratories, #FinancialSummary, #InterimResults","jir_key_figures":"Net Sales: 563,168 thousand yen\nOperating Income: 197,477 thousand yen\nNet Income Attributable to Owners of Parent (Interim): 186,570 thousand yen","jir_meta_title":"Immuno-Biological Laboratories Co., Ltd. \u2014 2nd Quarter Financial Summary | November 11, 2026","jir_meta_description":"Summary of Immuno-Biological Laboratories Co., Ltd.'s 2nd quarter results for the fiscal year ending March 2027: net sales 563 million yen, operating income 197 million yen, net income 186 million yen. Includes full-year outlook and segment trends.","jir_og_title":"Immuno-Biological Laboratories Co., Ltd. 2nd Quarter Financial Summary","jir_og_description":"2nd quarter results for the fiscal year ending March 2027: net sales 563 million yen, operating income 197 million yen, net income 186 million yen. Full-year outlook included.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58169,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-149184","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n